Cargando…
Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study
OBJECTIVE: To assess the effect of HIV infection and combined antiretroviral therapy (c-ART) on various proatherogenic biomarkers and lipids and to investigate their relationship with subclinical atherosclerosis in a cohort of treatment-naive HIV-infected patients. METHODS: We performed a prospectiv...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446923/ https://www.ncbi.nlm.nih.gov/pubmed/32817629 http://dx.doi.org/10.1371/journal.pone.0237739 |
_version_ | 1783574217406545920 |
---|---|
author | Di Yacovo, Silvana Saumoy, Maria Sánchez-Quesada, José Luís Navarro, Antonio Sviridov, Dmitri Javaloyas, Manuel Vila, Ramon Vernet, Anton Low, Hann Peñafiel, Judith García, Benito Ordoñez-Llanos, Jordi Podzamczer, Daniel |
author_facet | Di Yacovo, Silvana Saumoy, Maria Sánchez-Quesada, José Luís Navarro, Antonio Sviridov, Dmitri Javaloyas, Manuel Vila, Ramon Vernet, Anton Low, Hann Peñafiel, Judith García, Benito Ordoñez-Llanos, Jordi Podzamczer, Daniel |
author_sort | Di Yacovo, Silvana |
collection | PubMed |
description | OBJECTIVE: To assess the effect of HIV infection and combined antiretroviral therapy (c-ART) on various proatherogenic biomarkers and lipids and to investigate their relationship with subclinical atherosclerosis in a cohort of treatment-naive HIV-infected patients. METHODS: We performed a prospective, comparative, multicenter study of 2 groups of treatment-naive HIV-infected patients (group A, CD4>500 cells/μL, not starting c-ART; and group B, CD4<500 cells/μL, starting c-ART at baseline) and a healthy control group. Laboratory analyses and carotid ultrasound were performed at baseline and at months 12 and 24. The parameters measured were low-density lipoprotein (LDL) particle phenotype, lipoprotein-associated phospholipase A2 (Lp-PLA2), interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), sCD14, sCD163, monocyte chemoattractant protein-1(MCP-1), and asymmetric dimethylarginine (ADMA). A linear mixed model based on patient clusters was used to assess differences in biomarkers between the study groups and over time. RESULTS: The study population comprised 62 HIV-infected patients (group A, n = 31; group B, n = 31) and 22 controls. Age was 37 (30–43) years, and 81% were men. At baseline, the HIV-infected patients had a worse LDL particle phenotype and higher plasma concentration of sCD14, sCD163, hs-CRP, and LDL-Lp-PLA2 than the controls. At month 12, there was an increase in total cholesterol (p = 0.002), HDL-c (p = 0.003), and Apo A-I (p = 0.049) and a decrease in sCD14 (p = <0.001) and sCD163 (p<0.001), although only in group B. LDL particle size increased in group B at month 24 (p = 0.038). No changes were observed in group A or in the healthy controls. Common carotid intima-media thickness increased in HIV-infected patients at month 24 (Group A p = 0.053; group B p = 0.048). Plasma levels of sCD14, sCD163, and hs-CRP correlated with lipid values. CONCLUSIONS: In treatment-naive HIV-infected patients, initiation of c-ART was associated with an improvement in LDL particle phenotype and inflammatory/immune biomarkers, reaching values similar to those of the controls. HIV infection was associated with progression of carotid intima-media thickness. |
format | Online Article Text |
id | pubmed-7446923 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-74469232020-08-31 Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study Di Yacovo, Silvana Saumoy, Maria Sánchez-Quesada, José Luís Navarro, Antonio Sviridov, Dmitri Javaloyas, Manuel Vila, Ramon Vernet, Anton Low, Hann Peñafiel, Judith García, Benito Ordoñez-Llanos, Jordi Podzamczer, Daniel PLoS One Research Article OBJECTIVE: To assess the effect of HIV infection and combined antiretroviral therapy (c-ART) on various proatherogenic biomarkers and lipids and to investigate their relationship with subclinical atherosclerosis in a cohort of treatment-naive HIV-infected patients. METHODS: We performed a prospective, comparative, multicenter study of 2 groups of treatment-naive HIV-infected patients (group A, CD4>500 cells/μL, not starting c-ART; and group B, CD4<500 cells/μL, starting c-ART at baseline) and a healthy control group. Laboratory analyses and carotid ultrasound were performed at baseline and at months 12 and 24. The parameters measured were low-density lipoprotein (LDL) particle phenotype, lipoprotein-associated phospholipase A2 (Lp-PLA2), interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), sCD14, sCD163, monocyte chemoattractant protein-1(MCP-1), and asymmetric dimethylarginine (ADMA). A linear mixed model based on patient clusters was used to assess differences in biomarkers between the study groups and over time. RESULTS: The study population comprised 62 HIV-infected patients (group A, n = 31; group B, n = 31) and 22 controls. Age was 37 (30–43) years, and 81% were men. At baseline, the HIV-infected patients had a worse LDL particle phenotype and higher plasma concentration of sCD14, sCD163, hs-CRP, and LDL-Lp-PLA2 than the controls. At month 12, there was an increase in total cholesterol (p = 0.002), HDL-c (p = 0.003), and Apo A-I (p = 0.049) and a decrease in sCD14 (p = <0.001) and sCD163 (p<0.001), although only in group B. LDL particle size increased in group B at month 24 (p = 0.038). No changes were observed in group A or in the healthy controls. Common carotid intima-media thickness increased in HIV-infected patients at month 24 (Group A p = 0.053; group B p = 0.048). Plasma levels of sCD14, sCD163, and hs-CRP correlated with lipid values. CONCLUSIONS: In treatment-naive HIV-infected patients, initiation of c-ART was associated with an improvement in LDL particle phenotype and inflammatory/immune biomarkers, reaching values similar to those of the controls. HIV infection was associated with progression of carotid intima-media thickness. Public Library of Science 2020-08-20 /pmc/articles/PMC7446923/ /pubmed/32817629 http://dx.doi.org/10.1371/journal.pone.0237739 Text en © 2020 Di Yacovo et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Di Yacovo, Silvana Saumoy, Maria Sánchez-Quesada, José Luís Navarro, Antonio Sviridov, Dmitri Javaloyas, Manuel Vila, Ramon Vernet, Anton Low, Hann Peñafiel, Judith García, Benito Ordoñez-Llanos, Jordi Podzamczer, Daniel Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study |
title | Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study |
title_full | Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study |
title_fullStr | Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study |
title_full_unstemmed | Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study |
title_short | Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study |
title_sort | lipids, biomarkers, and subclinical atherosclerosis in treatment-naive hiv patients starting or not starting antiretroviral therapy: comparison with a healthy control group in a 2-year prospective study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446923/ https://www.ncbi.nlm.nih.gov/pubmed/32817629 http://dx.doi.org/10.1371/journal.pone.0237739 |
work_keys_str_mv | AT diyacovosilvana lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy AT saumoymaria lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy AT sanchezquesadajoseluis lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy AT navarroantonio lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy AT sviridovdmitri lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy AT javaloyasmanuel lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy AT vilaramon lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy AT vernetanton lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy AT lowhann lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy AT penafieljudith lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy AT garciabenito lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy AT ordonezllanosjordi lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy AT podzamczerdaniel lipidsbiomarkersandsubclinicalatherosclerosisintreatmentnaivehivpatientsstartingornotstartingantiretroviraltherapycomparisonwithahealthycontrolgroupina2yearprospectivestudy |